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Background. Preventive and therapeutic vaccine strategies aimed at controlling hepatitis C virus (HCV)
infection should mimic the immune responses observed in patients who control or clear HCV, specifically T help-
er (Th) type 1 and CD8+ cell responses to multiple antigens, including nonstructural protein (NS) 3. Given the
experience with human immunodeficiency virus, the best candidates for this are based on DNA prime, pox, or
adenovirus boost regimens.
Methods. In rhesus macaques, we compared NS3-expressing DNA prime and adenovirus boost strategy with
2 alternative priming approaches aimed at modifying Th1 and CD8+ responses: DNA adjuvanted with interleukin
(IL)–2– and –12–encoding plasmids or Semliki Forest virus (SFV).
Results. All prime-boost regimens elicited NS3-specific B and T cell responses in rhesus macaques, including
CD8+ responses. SFV priming induced higher lymphoproliferation and longer Th1 memory responses. The use
of IL-2– and IL-12–expressing vectors resulted in reduced Th2 and antibody responses, which led to increased Th1
skewing but not to an increase in the magnitude of the IFN-g and CD8+ responses.
Conclusions. All strategies induced Th1 cellular responses to HCV NS3, with fine modulations depending on
the different priming approaches. When they are developed for more HCV antigens, these strategies could be
beneficial in therapeutic vaccine approaches.
Hepatitis C virus (HCV) is the major cause of chronic
liver infection; it leads to severe liver damage, includ-
ing cirrhosis and hepatocellular carcinoma [1]. Pro-
phylactic and therapeutic approaches to prevent HCV
hepatitis are urgently needed [2]. Although information
regarding the immune correlates of protective immu-
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nity is incomplete, current evidence points to the piv-
otal role played by HCV-specific cellular immune re-
sponse in the control and clearance of HCV infection
[3]. In particular, nonstructural protein (NS) 3–specif-
ic Th1 responses have been linked to viral clearance in
humans [4, 5], and NS3-specific CD8+ responses have
been described in the treatment-linked resolution of
infection [6]. In chimpanzees, early viral clearance and
protection from chronic infection have been associated
with induction of interferon (IFN)–g in the liver [7]
and with envelope- and NS3-specific IFN-g–secreting
cells in the periphery [8].
To induce such immune responses, priming of the
immune system is critical. Faulty priming that results
in an inappropriate skewing of the immune system may
be irreversible, and it may have dramatic adverse effects
[9, 10]. T cell immunity can be induced against a variety
of pathogens in different animal models by vaccine vec-
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Table 1. Rates of seroconversion to nonstructural protein (NS) 3 after each immunization and after
long-term follow-up (week 45).
Vaccine group
Antibody responders to NS3
After first
prime
After second
prime
After first
adenovirus
After second
adenovirus Week 45
Group 1, DNA and adenovirus 0/3 1/3a 2/3 3/3 3/3
Group 2, DNA, IL, and adenovirus 0/4 0/4 1/4 4/4 1/4
Group 3, SFV and adenovirus 0/4 1/4b 1/4 2/4c 1/4b
Total 0/11 2/11 4/11 9/11 5/11
NOTE. Results are expressed as no. of macaques showing an antibody response to NS3/total no. of macaques in the
group. IL, interleukin; SFV, Semliki Forest virus.
a Macaque Ri499.
b Macaque C056.
c Macaques C228 and Ri426 did not mount any detectable anti-NS3 antibody response.
Figure 1. Anti–nonstructural protein (NS) 3 helicase antibody response
in macaque groups primed with DNA and DNA plus cytokines. ELISA an-
tibody titers are represented for each rhesus macaque in group 1, which
were primed with DNA-NS3 alone (black lines and symbols) and of group
2, primed with DNA-NS3 plus interleukin (IL)–2 and IL-12 (gray lines and
white symbols). White arrows represent the 2 priming injections; black
arrows represent the 2 boosting injections. Results for group 3, primed
with Semliki Forest virus and NS3, are not shown; only 2 of 4 macaques
seroconverted. *Significant difference observed between the 2 groups
(week 45, ).Pp .04
tors, including DNA plasmids [8, 11–13] and recombinant viral
vectors, such as Semliki Forest virus (SFV) [14, 15] and ade-
novirus [16]. Prime-boost immunization approaches with het-
erologous vectors are now being widely tested against different
pathogens and are acceptable for human use [17]. We used
adenovirus as a boosting agent because it infects a broad spec-
trum of human cells, including dendritic cells, which leads to
efficient antigen presentation [18, 19] and therefore may en-
hance the immune responses induced by different priming vec-
tors, such as DNA and SFV. The low-level immune responses
elicited by DNA vaccines can also be influenced by combining
them with cytokines, as has been demonstrated in the context
of HIV in rhesus macaques [20–23]. We used plasmids encod-
ing 2 interleukins (ILs) that favor the development of Th1
immune responses—IL-12 and IL-2 [22, 24]. Finally, the use
of viral vaccine vectors such as SFV may have the advantage
over plasmid DNA of mimicking a transient virus infection
and, thus, recruiting innate antiviral responses [25, 26].
Although DNA, SFV, and adenoviral vectors have been eval-
uated in macaques as vaccine candidates for HIV, they have been
the focus of only a small number of studies of HCV, which were
limited to mice [27]. However, observations in mice can rarely
be translated directly to humans, particularly those that concern
Th1/Th2 response skewing. Besides humans, chimpanzees are
the only species susceptible to chronic HCV infection; however,
their use in research is highly restricted. Therefore, human clini-
cal trials of HCV vaccine candidates may be guided by com-
parative immunogenicity studies in nonhuman primates, such
as rhesus macaques. Although they are not susceptible to HCV
infection, rhesus macaques are a suitable model for preclinical
immunogenicity studies because they are phylogenetically and
physiologically similar to humans [28]. Their well-characterized
immune system is comparable to that of humans in terms of
cytokine production and regulation [29]. HCV vaccine candi-
dates based on recombinant viral proteins (core and, most re-
cently, virus-like particles [VLPs]) have been tested for immu-
nogenicity in macaques and baboons [30, 31]. To date, there has
been no knowledge of the responses induced in nonhuman pri-
mates by viral vectors encoding HCV antigens, and the results
obtained in primates with vectors encoding other antigens, such
as those for HIV, may not predict the responses obtained with
HCV antigens that possess immunomodulatory functions [32–
34]. We investigated the immunogenicity and fine modulation
of B and T cell immune responses induced in nonhuman pri-
mates by comparing DNA and SFV priming in combination with
adenovirus boosting. We used a clinically relevant HCV NS3 gene
as a first screening step before incorporating other key HCV
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Figure 2. Anti-adenovirus antibody responses. Anti-adenovirus antibody titers are represented for all rhesus macaques at weeks 16, 20, 22, and 24.
All macaques had undetectable anti-adenovirus antibody levels before the injection of adenovirus (data not shown). Immunizations with adenovirus–non-
structural protein (NS) 3 were performed at weeks 14 and 20. The immunization regimen for all macaques is indicated. SFV, Semliki Forest virus. *Two
macaques (Ri499 and C056) seroconverted to NS3 after priming. #Two macaques (C228 and Ri426) did not elicit anti-NS3 antibodies at any time.
Figure 3. Lymphoproliferation to nonstructural protein (NS) 3 helicase protein. The individual stimulation indices (SIs) from each rhesus macaque from
the 3 groups are shown. White bars indicate levels before immunization. Gray bars indicate levels after prime (week 8 or 12), after the first injection of
NS3-adenovirus (week 16 or 20), after the second injection of NS3-adenovirus (week 22 or 24) (for these 3 time points, the better result for each macaque
is shown), and week 45. Lymphoproliferation was considered to be positive when the SIs (counts per minute with antigen divided by background counts
per minute with medium alone) was 12. The immunization regimen for all macaques is indicated. SFV, Semliki Forest virus.
antigens, such as the structural proteins. These studies may be
useful in the selection of vaccine candidates for efficacy testing.
MATERIALS AND METHODS
Macaques. The present study and the experimental proce-
dures used in 12 naive rhesus macaques (Macaca mulatta) were
approved by the institute’s animal ethical and use committee
and were performed in accordance with Dutch and interna-
tional guidelines for the use of animals in science. Serum and
peripheral blood mononuclear cells (PBMCs) were isolated from
blood samples collected from sedated macaques at regular time
points by use of aseptic techniques (Vacutainer; Becton Dick-
inson). Body weight, temperature, and hematologic and bio-
chemical clinical values were monitored at regular intervals.
Peptides and recombinant NS3 protein. Seventy-eight
15-mer peptides with overlaps of 7 amino acids covering the
NS3 region of the same HCV genotype 1b J strain [35] as
that used for immunization were purchased from Clonestar
Biotech. The NS3 helicase (aa 1193–1458) of HCV genotype
1a [36] was expressed in Escherichia coli and purified as de-
scribed elsewhere [37].
NS3-expressing vaccine vectors. All immunogens used to
immunize monkeys (DNA, SFV, and adenovirus) were based on
the HCV genotype 1b J strain [35]. The DNA-NS3 plasmid
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Figure 4. Individual balance of nonstructural protein (NS) 3 helicase–specific Th1 (interleukin [IL]–2 and interferon [IFN]–g) and Th2 (IL-4) cytokine
production by peripheral blood mononuclear cells (PBMCs). Cells secreting IL-2 (left panels, black bars), IFN-g (middle panels, black bars), and IL-4
(right panels, dashed bars), as tested by enzyme-linked immunospot assay, are shown for each macaque from each group (group 1, DNA priming;
group 2, DNA plus IL priming; and group 3, Semliki Forest virus [SFV] priming) after prime boost (week 8 or 12), after the first injection of NS3-
adenovirus (week 16 or 20), after the second injection of NS3-adenovirus (week 22 or 24) (the better result for each macaque is shown), and at week
45 (referred to as “long-term follow-up”). Results are expressed as mean no. of spot-forming cells in triplicate assays per 106 cells minus the cutoff
(the mean no. of spot-forming cells obtained with the cells cultured in medium, also in triplicate assays, plus 2 SDs). Macaque identities are not
indicated, but macaques are consistently represented for each group from top to bottom: group 1, C134, C168, and Ri499; group 2, C139, C172, Ri489,
and Ri498; and group 3, C056, C154, C228, and Ri426. *Statistically significant difference with the other groups ( , analysis of variance).P ! .05
contains the NS3 gene (nt 3419–5311; aa 1027–1657), cloned
into the high-expression gWIZ vector (Gene Therapy Systems)
under the control of a modified cytomegalovirus promoter [38].
For SFV-NS3 particles, the NS3 fragment was inserted into an
SFV expression vector. The packaging of RNA into recombinant
SFV particles was facilitated by use of a 2-helper RNA system
described elsewhere [39]. The production of NS3 was confirmed
by in vitro transfection, pulse chase, and immunoprecipitation
(data not shown). The NS3-expressing type 5 replication–defec-
tive adenovirus (NS3-adenovirus) has been described elsewhere
[37]. HCV NS3-encoding DNA, SFV, and adenovirus constructs
elicited, alone or in prime-boost combinations, Th1 immune
responses in mouse models [37, 38, 40, 41].
IL-encoding DNA plasmids. The human (h) IL-2/Ig plas-
mid pVRC-hIL2/Ig (DNA–IL-2), which encodes a fusion pro-
tein consisting of IL-2 and the Fc portion of IgG [21], was
provided by Dr. Dan Barouch (Beth Israel Deaconess Medical
Center, Boston, MA). In rhesus macaques, this markedly aug-
ments DNA vaccine-elicited HIV-1 and simian immunodefi-
ciency virus (SIV)–specific immune responses [21]. The plas-
mid pNDI–IL-12, which encodes rhesus IL-12b (DNA–IL-12;
provided by Francois Villinger, Emory University, Atlanta, GA),
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Figure 5. Individual cumulative nonstructural protein (NS) 3 peptide pool–specific interferon (IFN)–g production by peripheral blood mononuclear
cells (PBMCs). Production of IFN-g to NS3 peptide pools (pp) 1–5, as tested by enzyme-linked immunospot assay, are shown for each macaque from
each group after prime boost (A, week 8 or 12) and after the injection of NS3-adenovirus (B, week 16, 20, 22, or 24) (the better result for each
macaque is represented). Results are expressed as mean no. of spot-forming cells in triplicate assays per 106 cells minus the cutoff (the mean no.
of spot-forming cells obtained with the cells cultured in medium, also in triplicate assays, plus 2 SDs). SFV, Semliki Forest virus.
has been reported to enhance DNA vaccine-induced protection
of rhesus macaques against SIV challenge [42]. All plasmid
DNAs were extracted and purified by use of Qiagen EndoFree
Plasmid Kits (Qiagen).
Immunizations. The 3 prime-boost vaccine combinations
were tested in 3 groups of 4 macaques each. The first group
received the DNA prime and adenovirus boost, the second group
received the DNA plus cytokine-encoding plasmids prime and
adenovirus boost, and the third group received the SFV prime
and adenovirus boost. The priming consisted of 2 injections at
weeks 0 and 6, and the NS3-adenovirus boosters were admin-
istered at weeks 14 and 20. A prime is the first time an antigen
is encountered, but, for brevity, the first and second immu-
nizations (DNA or SFV) will be referred to as “prime,” and
the third and fourth injections (adenovirus) will be referred to
as “boost.” For each DNA immunization, 1 mg of DNA-NS3
suspended in saline buffer was equally divided intramuscular-
ly and intradermally. For group 2, 1 mg of DNA–IL-12 was
coadministered with DNA-NS3, and 1 mg of DNA–IL-2 was
administered 2 days later at the same sites. For SFV-NS3 im-
munization, pfu dissolved in saline were injected sub-85 10
cutaneously. All macaques were boosted subcutaneously with
pfu NS3-adenovirus at week 14 and with 51010 pfu95 10
at week 20. No adverse effects or lesions associated with the
inoculations were found. One macaque from the first group
died of an unrelated health problem at week 6, reducing group
1 (DNA and adenovirus) to 3 macaques.
Humoral immune responses. Quantification of anti-ade-
novirus antibodies was performed in serum by an independent
hospital laboratory (Erasmus MC—Virology), by use of a quan-
titative ELISA (SERION adenovirus IgG/IgA) that detects an-
tibodies to the 8 most prevalent serotype-specific epitopes. HCV-
NS3–specific antibodies were detected in serum by ELISA for
which microtiter plates were coated with NS3 helicase recom-
binant protein (0.5 mg/mL). Serum samples were screened at
a dilution of 1:100. Positive samples were serially diluted to
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Figure 6. Individual production of interferon (IFN)–g to nonstructural protein (NS) 3 peptide pools (pp) by CD4+ and CD8+ cells. A, NS3 peptide–
specific IFN-g–positive CD4+ (gray bars) and CD8+ (black bars) responses were analyzed in all rhesus macaques by an intracellular staining assay after
injections of adenovirus (week 20 or 24; the better result for each macaque is shown). Results are expressed as corrected no. of NS3-specific IFN-
g–positive CD4+ or CD8+ cells per 106 lymphocytes (no. of IFN-g–positive CD4+ or CD8+ cells with NS3 peptide pool minus the no. of IFN-g–positive
CD4+ or CD8+ cells with an irrelevant hepatitis C virus [HCV] E2 peptide pool). B, As an example, the flow-cytometric dot plots of the IFN-g– and IL-
2–producing CD8+ cells from macaque C134 stimulated with the irrelevant HCV E2 peptide pool (left panel, negative control) and with the HCV NS3
peptide pool (right panel) are represented. Lymphocytes are gated for CD3+ and CD8+ surface markers. PBMC, peripheral blood mononuclear cells.
obtain end-point titers. Detection was performed with per-
oxidase-conjugated Affinipure goat anti–human IgG (Jackson
Immunoresearch), diluted to 1:10,000. The cutoff was deter-
mined as the mean value obtained with serum from 3 naive
blood donors +3 SDs. Serum was considered to be positive
when the absorbance was equal to or superior to this cutoff.
Cellular immune responses. Lymphoproliferation was mea-
sured by 3H-thimidine incorporation, as described elsewhere
[34]. Quantification of specific cytokine-secreting cells was per-
formed by IFN-g, IL-2, and IL-4 enzyme-linked immunospot
(ELISPOT) assays, according to the manufacturer’s instructions
(U-Cytech), by use of concanavalin A (ConA; 5 mg/mL), NS3
helicase protein (4 mg/mL), peptides covering NS3 or HIV-1SF2
gag p24 (4 mg/mL; provided by the late Kathelyn Steimer, Chi-
ron, Emeryville, CA) or medium alone. Results are expressed
as the mean number of spot-forming cells per 106 cells from
triplicate assays minus the cutoff (mean number of spot-form-
ing cells plus 2 SDs obtained with triplicate medium assay).
Phenotyping by intracellular cytokine staining (ICS) assay.
The phenotype of responding T cells was analyzed by use of ICS
assay, as described elsewhere [43], by stimulating PBMCs with
ConA, NS3, or E2 peptide pools (5 mg/mL) or with medium
alone and by staining with fluorescein isothiocyanate–labeled
anti-CD3, peridinin-chlorophyll-protein complex–labeled anti-
CD8, and allophycocyanin-labeled anti–IFN-g antibodies (BD
Pharmingen). Results are expressed as the corrected number
of specific IFN-g–positive CD4+ or CD8+ cells per 106 lym-
phocytes, according to the method of Barouch et al. [22]: num-
bers of IFN-g–positive CD4+ or CD8+ cells with the NS3 peptide
pool minus the numbers of IFN-g–positive CD4+ or CD8+ cells
with the irrelevant E2 peptide pool.
Statistical analysis. Statistical analysis was performed by
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analysis of variance and t tests, with 2-tailed P values calculated
by exact methods. was considered to be significant.P ! .05
RESULTS
Influence of priming on the antibody responses. The priming
injections were poor inducers of antibody responses in rhesus
macaques (table 1). After 2 adenovirus boosts, all 7 macaques
primed with DNA seroconverted, whereas this was true for
only 2 of 4 SFV-NS3–primed macaques. In the macaques that
received only DNA, 2 of 3 had seroconverted after the first
adenovirus injection, as did 1 of 4 in the cytokine-adjuvanted
group. Analysis of the antibody titers in these DNA-primed
groups suggested that the macaques primed with NS3 plus
plasmids encoding IL-2 and IL-12 had lower antibody titers
(range, 100–1600), compared with the macaques primed with
DNA-NS3 alone (range, 800–51,200) (figure 1). The antibody
response was higher in the DNA-primed group at week 45
( ).Pp .04
Transient anti-adenovirus humoral responses were induced
in all macaques, peaking 2 weeks after the first adenovirus in-
jection (3.19–122.0 U/mL at week 16; figure 2) and decreasing
to undetectable levels at week 28 (data not shown). The 3
priming vectors did not influence the adenovirus-specific hu-
moral response. Two macaques that seroconverted to NS3 after
priming (Ri499 and C056) mounted higher responses to the
adenoviral vector (122 and 94 U/mL, respectively) than did the
others (maximum, 40.3 U/mL), which suggests that NS3-spe-
cific T helper cells elicited by the priming immunizations pro-
vided T cell help to the adenovirus-specific B cells. Except for
these cases, there was no correlation between the anti-NS3 and
the anti-adenovirus antibody titers. The 2 SFV-NS3–primed
macaques that did not seroconvert to NS3 (C228 and Ri426)
had anti-adenovirus antibody responses (19.4 and 28.8 U/mL,
respectively; figure 2), which confirms that the absence of NS3
seroconversion was not due to an improper injection of NS3-
adenovirus. Owing to the likelihood of preexisting adenovirus
immune responses limiting the second boost, we elected to use
a 10-fold-higher second dose. Despite this, the second admin-
istration of NS3-adenovirus elicited a lower response (from 0
to 19.4 at weeks 22 and 24; figure 2).
Impact of priming on lymphoproliferative responses. Both
combinations involving DNA-NS3 priming were poor induc-
ers of lymphoproliferative responses, compared with the SFV-
primed macaques ( ; figure 3). Only 2 of 7 DNA-primedPp .04
macaques (C134 and C139) showed proliferation (stimulation
indices [SIs] peaking at 7.9 and 4.3, respectively), whereas the
other macaques had a marginal or no response ( ). InSI 2.7
contrast, 3 of 4 macaques immunized with SFV-adenovirus
developed higher NS3-specific lymphoproliferative responses,
with SIs of 6.8–15.3 ( ). However, this response becamePp .04
undetectable at week 45 in almost all macaques (figure 3).
Differential induction of Th1/Th2 cytokine secretion. We
counted the NS3 protein–specific IL-2–, IFN-g–, and IL-4–
secreting cells (figure 4). Although we did not separate CD8+
cells from the PBMCs, the cells responding to proteins in the
ELISPOT assay most likely were CD4+ cells [44]. All 3 vaccine
regimens induced IL-2 responses to NS3, with comparable in-
tensity and kinetics between groups (figure 4). Most responses
were obtained after the first injection of NS3-adenovirus (range,
10–105 sfc/106 cells) and were not boosted by the second in-
jection of NS3-adenovirus. Low numbers of IL-2–secreting cells
were still detectable 25 weeks after the last injection in 6 ma-
caques, 3 of which had been primed with SFV.
The 3 vaccine regimens were also able to induce NS3-specific
IFN-g–secreting T cells that largely exceeded the IL-4 responses
(figure 4). Surprisingly, the use of cytokine-encoding plasmids
blocked IFN-g production after the priming injection (Pp .03).
After the first injection of NS3-adenovirus, IFN-g responses in
all 3 groups were equivalent (range, 15–150 sfc/106 cells) and
were not further increased by the second adenovirus boost
(figure 4). IFN-g responses became undetectable by week 28
in all 7 DNA-primed macaques, whereas SFV priming elicited
IFN-g responses in macaques up to week 45 ( ). NS3-Pp .02
specific IL-4–producing cells were induced after the injections
of NS3-adenovirus in only 6 of 11 macaques and were low in
all of them (range, 5–40 sfc/106 cells; figure 4). In particular,
DNA with IL-2 and IL-12 reduced the IL-4 responses to almost
undetectable levels (to !10 sfc/106 cells). Taken together, these
results demonstrate that the 3 vaccine regimens were able to
induce NS3 protein–specific Th1 responses, but priming with
IL-2 and IL-12 did not increase or prolong the IFN-g responses.
Induction of IFN-g responses to NS3 peptide pools. The
induction of NS3-specific CD8+ responses was a primary ob-
jective of our HCV vaccine experiments, because of the ob-
served benefit that cytotoxic T lymphocyte responses give in
the control of HCV infection. As a first screening, we undertook
an analysis of IFN-g production in response to 5 NS3 peptide
pools (pp) covering the entire NS3 protein: pp1 covered aa
1028–1154, pp2 covered aa 1148–1274, pp3 covered aa 1268–
1402, pp4 covered aa 1395–1530, and pp5 covered aa 1524–
1644 (pp1 and pp5 covered regions that were not included in
the NS3 helicase recombinant protein). Before the adenovirus
injections, low IFN-g production specific to pp1, pp4, and pp5
was induced in macaques C134 and C168, which had been
primed with DNA-NS3 (20 and 75 sfc/106 cells, respectively;
figure 5A). After the injections of NS3-adenovirus, 9 of 11 ma-
caques in all groups had strong IFN-g responses to 1 peptide
pool, with cumulative responses reaching 1150 sfc/106 cells. At
week 28, most peptide pool–specific responses were !45 sfc/106
cells in all groups (data not shown).
Phenotype of the NS3 peptide–specific response. We in-
vestigated the phenotype of the NS3 peptide–specific IFN-g–
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producing T cells using the ICS assay. Samples obtained after
adenovirus infection were analyzed by use of a single NS3 pep-
tide pool including pp1–pp5. Our results demonstrated that
high peptide-specific IFN-g production was due to CD8+ cells,
with NS3-specific IFN-g–positive CD8+ cell counts of 13–1588
cells/106 PBMCs (figure 6). Significantly lower responses were
observed in the IL-2 and IL-12 group, compared with the 2
other groups ( ).Pp .02
DISCUSSION
We evaluated the immunogenicity of 3 vaccine regimens aimed
at inducing Th1 and CD8+ immune responses to the HCV NS3
antigen in a nonhuman primate model, the rhesus macaque. We
compared a DNA prime, DNA plus IL-2 and IL-12 prime, and
an SFV prime, all of which were combined with an adenovirus
boost. Although similar studies have been performed with HIV,
these vaccine combinations are unique in the field of HCV. Our
results showed that all vaccine regimens were able to induce B
cell, Th1, and CD8+ cell responses, with fine differences.
The priming agents DNA and SFV alone were not able to
induce good antibody responses in rhesus macaques, whereas
the blocking with the adenovirus was highly efficient, as has
been demonstrated elsewhere [45]. Similarly, B cell responses
can be elicited with HIV DNA or SFV immunization alone [46,
47]; however, viral vector boosting is beneficial for reaching
significant titers [48, 49]. A lower and short-lived B cell re-
sponse was obtained with the IL-2 and IL-12 priming, as was
expected, given that the induction of a Th1 bias should have
counteracted and limited the Th2 response [50]. Therefore, the
cytokine priming had a long-lasting effect, because the first and
second adenovirus immunizations occurred 8 and 16 weeks,
respectively, after the last cytokine injection, which empha-
sizes the importance of the “imprinting” left during the first
encounter of the immune system with an antigen.
Similar to the B cell response, most NS3-specific cellular re-
sponses were observed after adenovirus boosting. As with HIV
constructs, plasmid DNA alone does not elicit T cell responses
of sufficient magnitude in primates [34]. We observed that the
second injection of adenovirus did not increase the NS3-specific
cellular immune responses, even while it elicited a reduced an-
ti-adenovirus antibody response. This suggests that the 10-fold-
higher dose administered at the second injection was neutralized
by the antivector immune response. Indeed, the impact of pre-
existing immune memory on vaccine viral vectors and especially
adenovirus has previously been documented with other vaccines,
including HIV vaccines, in primates [51, 52]. Although it seems
that the second injection of adenovirus was beneficial for the
humoral response, this still could have been due to a delayed
effect of the first injection of adenovirus. In other studies, longer
intervals of 12 or 24 weeks allowed a second injection of ade-
novirus, which was shown to have a boosting effect on both
humoral and cellular responses in macaques and suggests that
the second injection of adenovirus has a boosting effect only af-
ter the specific cellular responses have undergone the contrac-
tion phase [53, 54]. The 2 injections of adenovirus in our study
were probably too close to each other.
As expected, and similar to results previously observed with
HIV vaccines for which IL-4 production was measured [34],
the 3 vaccine strategies induced Th1-biased immune responses
in primates, with IFN-g responses largely exceeding the IL-4
responses, and included the desired NS3-specific CD8+ re-
sponses. However, the cytokines increased the skewing of the
CD4+ response toward Th1 but did not increase the intensity
of the IFN-g and IL-2 responses and even decreased the CD8+
response. This is surprising, because both the IL-2 and IL-12
plasmids used in the present study have demonstrated their
potential to enhance and improve the efficacy of several T cell–
based HIV vaccines in macaques [21, 22]. The IL-12 dose re-
leased in the microenvironment of antigen-presenting cells
(APCs) and T cells seems to be crucial. In particular, a high
dose might block the function of APCs and reduce the im-
munogenicity of the coinjected antigen, as has been described
in mice [55, 56]. When DNA is used, the amount of cytokine
released locally should be low. However, because we did not
compare different doses, we cannot exclude the possibility that
1 mg of IL-12–encoding DNA produced too much IL-12 locally
and thus reduced the immunogenicity of DNA and NS3. The
observations that no IFN-g was detected after the priming in-
jections that included cytokines, in contrast with the 2 other
priming strategies ( ), and that the CD8+ responses werePp .03
lower ( ) point in this direction. The antigen itself mayPp .02
influence the quality of the immune responses, and this effect
might be dominant over the cytokine microenvironment, as
was shown recently for HIV antigens [34]. In vitro, HCV NS3
has been shown to induce IL-10 production by monocytes and
dendritic cells while reducing IL-2 production and differenti-
ation in the latter. Notably, this could be reversed by use of
anti–IL-10 antibodies but not by the addition of IL-12 [33].
This property could account for the differences observed be-
tween HIV vaccines and our HCV NS3–based vaccine.
The development of prophylactic and therapeutic vaccine
strategies against HCV infection cannot be limited to studies
in mice, because there is a big gap between the results of mice
and chimpanzee studies and those of human clinical trials. Al-
though a high number of vaccine candidates have been devel-
oped and tested in mice [57], very few have reached the pre-
clinical phase and have been tested in naive chimpanzees [8,
58, 59]. The use of nonhuman primates to investigate the im-
munogenicity of HCV vaccine candidates is a valid option, and
it may help in the selection of optimal vaccine candidates or
adjuvants and allow a detailed analysis of several aspects of the
immune responses. Both HCV vaccine candidates tested pre-
 at U
niversidad de N
avarra on A
pril 20, 2012
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
928 • JID 2005:192 (1 September) • Rollier et al.
viously in nonhuman primates (macaques and baboons) were
based on subunit proteins (core and VLPs, respectively) and
did not involve NS3 [30, 31]. Our vaccine regimens elicited
HCV-specific responses that were comparable in intensity to
those of responses observed in baboons immunized with VLPs,
and these responses mimic some of those observed in patients
recovering from HCV infection [5]. In conclusion, we have
demonstrated the utility of clinically relevant DNA and SFV
prime–adenovirus boost vaccine strategies for the induction of
HCV-specific Th1 and CD8+ cellular responses in primates and
have shown the effect of priming on the quality of the ultimate
vaccine-induced response.
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